Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Nakazawa S, Pecci F, Odintsov I, Gazgalis D, Gottlieb FH, Ricciuti B, Zullo L, Alessi JV, Di Federico A, Aldea M, Garbo E, Gandhi MM, Saini A, Feng WW, Jiang J, Baldacci S, Facchinetti F, Makarem M, Locquet MA, Haratani K, Haradon D, Besse B, Italiano A, Remon J, Lavaud P, Vasseur D, Planchard D, Sato Y, Watanabe Y, Owen S, Cortot AB, Mahran H, Forster MD, Niu J, Tomasini P, Leong SS, Tay K, Esteban E, Minchom A, Kizilbash SH, Cruz-Correa M, Yu KP, Zhang X, Chen P, Sangem M, Che J, Sholl LM, Jänne PA, Awad MM.
Nakazawa S, et al. Among authors: gandhi mm.
Cancer Discov. 2025 Jun 3;15(6):1129-1140. doi: 10.1158/2159-8290.CD-24-1726.
Cancer Discov. 2025.
PMID: 40202082